The Effectiveness of Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04205201

Enrollment

Registered

2019-12-19

Start date

2018-06-25

Completion date

2019-10-05

Last updated

2019-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients

Brief summary

Outpatient department of cmch, ceitc,cimch POAG patients enrolled for the study.

Interventions

DRUGDrugs, Investigational

To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Caregiver)

Masking description

Generated by pharmaceutical companies.

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* IOP 22\_34mmof Hg,newly diagnosed case, bilateral POAG patients Patients.

Exclusion criteria

* pregnant and lactating women, infection, any eye surgery.

Design outcomes

Primary

Measure	Time frame	Description
More than 20% IOP reduction	0_3 months	From baseline to month 3

Secondary

Measure	Time frame	Description
Adverse reaction	O_3 months	Record every follow up period baseline to month 3.

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026